**Neuroprotective Potentials of Andrographolide (AG) and its structural analogues in Alzheimer’s Disease (AD)**

**Bhattacharya Vijeta\*1, M. Alagusundaram1, Mishra Namrata1, Goli Venketeshswarlu2, Chopra Neha1**

1- Department of Pharmaceutics School of Pharmacy ITM University, Gwalior, Madhya Pradesh, 474001.

2-Department of Biotechnology School of Pharmacy, ITM University, Gwalior, Madhya Pradesh, 474001.

**Abstract:**

The traditional herb Andrographis paniculata (A. paniculata) has a long history of use in eastern Asia and ancient China for the treatment of a number of illnesses, including laryngitis, rheumatoid arthritis, cancer, diarrhoea, and upper respiratory tract infections. Andrographolide is a compound derived from this herb. One or more of andrographolide's disease prevention and/or therapy strategies include anti-inflammation, antioxidative stress, anti-apoptosis, and/or pro-apoptosis. Pharmacodynamic investigations have shown that andrographolide may cross the blood-brain barrier and distribute to numerous brain areas; as a result, its pharmacological effects on the central nervous system (CNS) have begun to be understood in recent years. For instance, andrographolide has been demonstrated in numerous models of cerebral ischemia to reduce the size of brain infarcts. These results suggest that andrographolide may be useful in the treatment of psychiatric disorders like anxiety and depression. Targeting treatments are part of the current AD treatment approach. The Food and Drug Administration has authorised the medication aducanumab, which is given intravenously and requires close patient monitoring because of a potentially harmful side effect known as amyloid-related imaging abnormalities (ARIA). There have been numerous scientific investigations on medicinal herbs. Due to their anti-inflammatory and antioxidant characteristics, herbs can be utilized to treat AD. Anti-inflammatory medications such as German chamomile, Ginseng, liquorice, turmeric, and white willow bark may decrease inflammation of the brain tissue in Alzheimer's. Researchers are working to create new medications with superior therapeutic efficacies. Andrographolide has been demonstrated to have therapeutic effects in a variety of AD models in several recent research. Inhibiting the neuroinflammatory response is thus a potential therapy option for AD. In this possible way, andrographolide and its derivative could offer a better choice to develop a novel therapeutic molecule to AD in near future.

**Key words:** andrographolide, Alzheimer’s disease, phytoconstituents, medicinal herbs, neuroprotective

**INTRODUCTION:**

With an estimated 30 million cases globally, Alzheimer's disease (AD) is the most prevalent cause of dementia. AD is a neurodegenerative disorder marked by gradual memory loss, diminished cognitive abilities, extensive neuronal death, and synaptic dysfunction[1].

Among the neuropathological indicators of AD amyloid precursor protein (APP), processing produces extracellular amyloid plaques and intracellular neurofibrillary tangles, which are primarily made of hyperphosphorylated tau protein[2,3]. The term "dementia" refers to a specific set of symptoms. Dementia is characterized by issues with memory, language, problem-solving, and other cognitive abilities. Dementia has numerous causes. [4-7] These reasons represent particular adjustments in the brain. One of the causes of dementia is Alzheimer's disease.**[8]** In addition to the loss of nerve cells, the aberrant proteins beta-amyloid and phosphorylated tau accumulate in the brains of people with Alzheimer's disease. The most frequent cause of dementia is the brain abnormalities brought on by Alzheimer's disease.[9]

By 2050, the number of people age 65 and older with Alzheimer's dementia is projected to reach 12.7 million. The incidence rate of Alzheimer's, or how many people per 100,000 are diagnosed with the disease for the first time each year, appears to be decreasing. [10] This trend has been attributed to reductions in risk factors for Alzheimer's disease over the course of the 20th century, like high blood pressure and illiteracy.[11] However, despite this possibly decreased incidence rate, it is anticipated that the number of persons with Alzheimer's will keep rising due to an increase in the population of adults 65 and older, who are at a higher risk of developing the disease.[12] It is unclear how COVID-19 will affect the amount and percentage of people who have Alzheimer's disease, including SARS-CoV-2 infection, COVID-19 mortality, and changes in healthcare access brought on by the COVID-19 pandemic.[13]Globally, over the course of the study, dementia incidence (147.95%),prevalence (160.84%), and death rate (189.29%) all increased significantly.

In 2021, there were 325,000 nurse practitioners in the United States, and 12% of them had specialized expertise in gerontological care. Less than 1% of registered nurses, physician assistants, and pharmacists identify themselves as specializing in geriatrics. However, 73% of social workers reported having experience working with older adults Members of the skilled care workforce—licensed healthcare specialists who deliver medically necessary nursing or rehabilitation services as directed by a doctor—are among those offering therapy.[14] Physical therapy, occupational therapy, wound care, intravenous injections, and catheter care are all included in this form of care, which can be provided either at home or at a skilled nursing facility.

The medicine aducanumab, which is administered via intravenous infusion and necessitates close patient observation due to a potentially dangerous side effect known as amyloid-related imaging abnormalities (ARIA), was approved by the Food and Drug Administration (for more information about aducanumab. [15-16] Aducanumab is administered intravenously, therefore infusion nurses are becoming essential components of the dementia care profession. Neuropsychologists and other medical experts with expertise in conducting cognitive tests are also crucial to determining whether aducanumab is helping people with Alzheimer's. Physicians may advise patients to stop taking aducanumab if they do not experience an improvement in their ability to think clearly and carry out everyday tasks while taking the medication. It is also necessary to investigate whether there are enough of these workers in the dementia care field to meet demand.[17]

A number of antibodies that have gone to phase 3 studies in patients with symptomatic AD have not demonstrated efficacy in terms of a significant reduction in the PET ligand signal or any clinically significant effects (ponezumab, solanezumab, bapineuzumab [48], crenezumab)

Numerous scientific studies on medicinal herbs have been conducted. Herbs can be used to treat AD because of their anti-inflammatory and antioxidant properties. Patients with Alzheimer's disease are lacking in acetylcholine. German chamomile, Ginseng, licorice, turmeric, and white willow bark are anti-inflammatory medicines that may lessen inflammation of the brain tissue in Alzheimer's.[18] A neurotransmitter that is essential for thinking and reasoning is acetylcholine. Acetylcholine levels in the brains of people with mild-to-moderate Alzheimer's disease, a degenerative form of dementia, are unusually low. Therefore, any substance that improves the cholinergic system in the brain may be helpful in treating Alzheimer's disease and other brain disorders. Natural COX-2 inhibitors, which are often referred to as medicinal herbs for AD indication, are present in herbs that inhibit Acetylcholinesterase (AchE). Some ayurvedic herbs, including Guduchi, Yashtimadhuk, Padma (Nelumbo nucifera), Vacha, Convolvulus pluricaulis, Shankhpushpi, Pancha-Tikta-Ghruta Gugguli, Amalaki, Musta Arjun, Ashwagandha, Galo Satva, Kutaj, Green Chiretta (Andrographolide), and others When used regularly, they improve the brain's capacity for function and hence offer stability.[19] In the early treatment of dementia and other disorders involving memory loss and Alzheimer's, herbs may hold promise. One of the chief benefits is that they have low toxicity compared to pharmaceutical agents. They are less toxic than pharmaceutical agents, which is one of their main advantages.[20] Botanicals can be used in conjunction with medications or other complementary therapies including SAMe, fish oil, and antioxidant vitamins.

It is important to compare the present pharmacological treatment for AD with the usage of natural remedies. Identification of the active principle should be a part of such investigations in order to strengthen clinical trial validation. To ascertain the effectiveness of these drugs in reversing the cognitive decline associated with AD, additional large-scale, multicentre investigations are required.[21]

The medicinal plant Andrographis paniculate contains andrographolide, a bicyclic diterpenoid lactone that has been shown to have antiviral, anti-inflammatory, anti-tumor, and anti-cardiovascular activities in the treatment of several disorders. Andrographolide can enter the brain, according to pharmacokinetic research, and it has anti-disease Parkinson's and anti-ischemic-reperfusion actions in the brain.[22]

These findings offer strong encouragement for the potential use of andrographolide in the treatment of AD. In reality, a clinical trial to evaluate the effectiveness of andrographolide as a treatment for AD patients has been described as both continuing and completed.[23]

**POSSIBLE RISK FACTORS OF AD:**

Alzheimer's disease, according to researchers, has multiple causes. It most likely results from a combination of variables, including genetics, way of life, and environment. The danger of developing Alzheimer's has been established by scientists. While there are some risk factors that cannot be modified, including as age, family history, and inheritance, new research indicates that there may be additional aspects that we can control.

A person with Alzheimer's experiences brain alterations. It has fewer healthy cells, and as time passes, it gets smaller. The brain cells frequently have two different kinds of defects as well:

• **Neurofibril tangles.** Inside brain cells, there are twisted fibers that prevent essential substances from flowing from one area of the cell to another.

* **Beta-amyloid plaques**. These are sticky clumps of proteins that build up between nerve cells instead of breaking down like they do in healthy brains.

Plaques and tangles damage the healthy brain cells around them. The damaged cells die, and the brain shrinks. These changes cause the symptoms of Alzheimer’s, such as memory loss, speech problems, confusion, and mood swings. Brain cells affected by the disease also make lower amounts of the chemicals called neurotransmitters that nerves use to send messages to each other.**[51,52]**

There are a few things that may make people more likely to get Alzheimer’s. So far, research has linked the disease with:

* **Age.** Your risk for Alzheimer's goes up as you get older. For most people, it starts going up after age 65.
* **Gender.** Women get the disease more often than men.
* **Family history.** People who have a parent or sibling with Alzheimer’s are more likely to get it themselves.
* [**Down syndrome**](https://www.webmd.com/children/guide/understanding-down-syndrome-basics)**.** It’s not clear why, but people with this disorder often get Alzheimer's disease in their 30s and 40s.
* **Head injury.** Some studies have shown a link between Alzheimer's disease and a major head injury.
* **Other factors.** High [cholesterol levels](https://www.webmd.com/cholesterol-management/goal-healthy-cholesterol-levels) and [high blood pressure](https://www.webmd.com/hypertension-high-blood-pressure/default.htm) may also raise your risk.

**CURRENT TREATMENT STRATEGIES OF AD:**

**Table-1 Current treatment strategies of Alzheimer disease**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Sr.no** | **Treatment Strategies of Alzheimer’s disease** | | **Side effects** | **Reference** |
| 1. | **Cholinesterase inhibitors** | According to the cholinergic hypothesis of AD, cholinergic systems in the basal forebrain are harmed early in the disease process, including loss of acetylcholine neurons and loss of enzymatic function for acetylcholine synthesis and degradation, which causes memory loss and deterioration of other cognitive and noncognitive functions like neuropsychiatric symptoms. It has been suggested that utilising CIs to postpone acetylcholine breakdown between synaptic clefts will improve cholinergic transmission. Currently, three CIs—donepezil (Pfizer, New York, NY, USA), rivastigmine (Novartis, Basel, Switzerland), and galantamine (Janssen, Beerse, Belgium)—are licenced for the treatment of mild to moderate AD [Farlow, 2002]. These medications have been recognised as the standard and first-line treatment for AD. | nausea, diarrhoea, vomiting, decreased appetite, dyspepsia, anorexia, muscle cramps, fatigue, insomnia, dizziness, headache, and asthenia. | 4,7,10,15,31,33 |
| 2. | **N-methyl-D-aspartate antagonist** | Memantine is an additional therapy choice for moderate-to-severe AD. An uncompetitive, moderate-affinity NMDA antagonist, this medication is thought to guard neurons from excitotoxicity. Memantine showed improvement in cognition, ADL, and behaviours in patients with moderate to severe AD after 6 months of administration, according to a systemic analysis of double-blind, parallel-group, RCT studies. Memantine may lessen the behavioural and psychological symptoms of dementia, according to another systemic review that comprised six RCT studies. | The most frequently reported adverse events in memantine trials were dizziness, headache and confusion. A small group of patients might develop agitation | 5,6,9,11,16 |
| **3.** | **Combination Therapy** | The combined therapy of memantine and donepezil compared to the placebo group significantly improved cognitive function, language, ADL, behavioural, and overall state in RCT investigations on parallel groups of patients with moderate to severe AD. However, patients with mild to moderate AD did not see this advantage. | nausea, diarrhoea, vomiting, decreased appetite, dyspepsia, anorexia, muscle cramps, fatigue, insomnia, dizziness, headache and confusion. | 7.10,18,21,23 |
| 4. | **Serotonin reuptake inhibitors** | For treating comorbid depression in AD dementia, fluoxetine, sertraline, paroxetine, citalopram, and fluvoxamine are generally regarded as some of the most effective antidepressants. | Possible side effects of SSRIs may include, among others:   * Nausea, vomiting or diarrhea * Headache * Drowsiness * Dry mouth * Insomnia * Nervousness, agitation or restlessness * Dizziness * Sexual problems, such as reduced sexual desire, difficulty reaching orgasm or inability to maintain an erection (erectile dysfunction) * Impact on appetite, leading to weight loss or weight gain | 14,17,19,22,25 |
| 5. | **Antipsychotics** | Atypical agents’ olanzapine, risperidone, quetiapine, ziprasidone and aripiprazole | The use of antipsychotics has been discussed controversially, as cerebrovascular morbidity and higher mortality have been found in patients with dementia taking antipsychotics. Furthermore, the use of antipsychotics may be associated with a higher risk of hip fracture and pneumonia, as well as worsening cognitive impairment. | 52,53,54 |
| 6. | **The amyloid hypothesis** | The Aβ is created by the successive proteolysis of the amyloid precursor protein (APP) by the enzymes secretase (BACE1) in the extracellular domain and secretase in the transmembrane region. Secretase (nonamyloidogenic pathway) or secretase (amyloidogenic pathway) first cleaves it within the luminal domain, almost completely shedding the ectodomain and producing C-terminal fragments (CTFs). A transmembrane aspartyl protease known as BACE1 (-site APP cleaving enzyme) is the principal neuronal secretase that cleaves APP within the ectodomain to produce the N-terminus of A. The intramembranous cleavage of and CTFs by secretase constitutes the second proteolytic step in APP processing. Positions 40 and 42 of A correspond to the primary sites of -secretase cleavage. | For decades, a battle has raged in the Alzheimer’s disease (AD) research community. On one side, adherents to the amyloid hypothesis, an evolving body of evidence that abnormal accumulation and aggregation of β-amyloid (Aβ) peptides (the main component of amyloid plaques) play a key role in triggering a cascade of pathological events that leads to the clinical syndrome of AD dementia | 13,19,20,23 |
| 7. | **Disease-modifying treatments** | A critical phase in the pathophysiology of AD, the synthesis of A, is caused by the cleavage of the overexpressed APP [Griffin, 2006]. A creates senile plaques, which are very insoluble and proteolysis-resistant fibrils (SPs). The tau protein makes up NFTs. The internal support structures for the movement of nutrients, vesicles, mitochondria, and chromosomes within the cell are called microtubules, and tau is a part of these structures in healthy individuals. As a result, in AD, both A and tau are important targets for disease-modifying treatments. According to this theory, AD could be prevented or efficiently treated by reducing the synthesis of A and tau, stopping their aggregation or misfolding, neutralising or eliminating their toxic aggregate or misfolded forms, or any combination of these methods. | swelling and small hemorrhages in the brain. | 14,29,35,38,44 |

**IMPORTANCE OF MEDICINAL PLANTS AND PHYTOCOMPOUNDS IN AD:**

Different phytocompounds found in medicinal plants can be extracted and used as raw materials for various scientific studies. Pharmaceutical enterprises use a variety of secondary metabolites from plants that are both commercially necessary and useful. Because they have fewer adverse effects than synthetic drugs and are necessary to address the growing demand for treatment, medicinal plants have recently acquired widespread popularity. According to several studies, medicinal plants like Centella Asiatica, Ginkgo biloba, Withania somnifera, Bacopa monnieri, Salvia officinalis, Melissa officinalis, Tinospora cordifolia, Glycyrrhiza glabra, etc. are used in the treatment of Alzheimer's disease. **[53-58]**

1. **Withania somnifera (Ashwagandha):**

In Ayurveda, Withania somnifera is frequently used as a nerve tonic that helps the body adjust to stress. W. The root of somnifera, a member of the Solanaceae family, is widely used. It has antioxidant and immune system-enhancing properties as well as free radical scavenging properties.8 W. Since somnifera has a soothing effect while other adaptogens tend to stimulate, it is effective in treating Alzheimer's disease in people.

1. **Bacopa monnieri (Brahmi):**

. The Scrophulariaceae family, which includes Bacopa monnieri, is found in wet and marshy environments. It is frequently used in Ayurvedic medicine and functions as a diuretic, a nerve tonic, a cardiotonic, and a treatment for asthma, insomnia, epilepsy, and rheumatism. Numerous phytochemicals found in this plant, including bacosides A and B, bacopasides III to V, and bacosaponins A, B, and C, as well as jujubogenin bisdesmosides bacopa saponins D, E, and F, betulic acid, sterols, alkaloids, polyphenols, and sulfhydryl compounds, have been linked to the plant's antioxidant activity. monnieri was used to improve memory and cognitive abilities. excerpts from B. monnieri's neuropharmacological effects and nootropic effects have been thoroughly studied. In the hippocampus, B. monnieri enhance protein kinase activity, which may explain how it improves memory. B. Monnieri likewise prevented monnieri also inhibited cholinergic degeneration and shows enhanced cognition effect in Alzheimer model of rat.

1. **Centella asiatica (Gotu Kola):**

Centella Asiatica belongs to the Apiaceae family and is found throughout India also in Sri Lanka and Bangladesh It contains various bioactive compounds which include triterpenes, asiatic acid, asiaticoside, adecassoside, sapogenins, glycosides, madecassic acid, vellarin, and centelloside Asiatic acid and asiaticoside showed reduce hydrogen peroxide-induced cell death, decline concentration of free radicals, and β-amyloid cell death inhibition in vitro which suggested possible role in Alzheimer’s disease treatment and β-amyloid toxicity prevention. Extracts of Centella asiatica reversed the β-amyloid pathology in mice brains and modulated oxidative stress response components. It is an important plant for nerve and brain cells and considers being capable of enhancing intellect, memory and longevity.

1. **Ginkgo biloba:**

The Ginkgo biloba plant is native to China and a member of the Ginkgoaceae family. excerpt from G. Biloba was used to cure headaches, depression, problems with insufficient blood circulation, and awareness loss. This extract was estimated to have about 24% flavonoids and 6% terpene lactones. There is substantial proof that standardized ginkgo extract exhibits a number of molecular and cellular neuroprotective processes, including the reduction of apoptosis, suppression of membrane lipid peroxidation, anti-inflammatory properties, and inhibition of amyloid aggregation formation. Regarding its potential significance in cognitive disorders, there have been numerous clinical investigations. Chronic treatment on learning and memory in mice revealed that G. Biloba improved two-response sequence acquisition, storage, and retrieval for food reward G. Biloba affects cognitive function in an animal model of Alzheimer's disease without changing the histopathological effects of the overexpressed amyloid precursor protein. G. Acetylcholinesterase activity is greatly reduced by ginkgo Biloba extract, and improvement in scopolamine-induced deficiencies in passive avoidance was observed when AChE activity was inhibited. Increased baseline levels of acetylcholine are indicated by decreased acetylcholinesterase activity.

1. **Curcuma longa (Turmeric):**

The Zingiberaceae family member Curcuma longa has anti-inflammatory properties that are also linked to a lower risk of Alzheimer's disease. Curcumin also slows the build-up of plaque in the brain. It reduces oxidative stress and amyloid pathology. Epidemiologic studies revealed that the prevalence of Alzheimer's disease is 4.4 times lower in Southeast Asian nations where turmeric is commonly consumed in food. One study found that low doses of curcumin reduced A levels in mice with Alzheimer's disease by up to 40% when compared to control drug. Curcumin's anti-inflammatory properties have been linked to a lower risk of Alzheimer's disease, according to another study. At a lesser dose, curcumin reduced the amount of A plaques that these mice with Alzheimer's disease have on their brains by 43%.

1. **Glycyrrhiza glabra:**

Glycyrrhiza glabra is a member of the Fabaceae family and contains a number of bioactive substances, such as linalool oxide, geraniol, benzoic acid, terpinen, tetramethyl pyrazine, propionic acid, ethyl linolenate, butanediol, feuferaldehyde, methyl ethyl ketone This might be advantageous for the treatment of AD.

1. **Lepidium meyenii:**

It is a member of the Brassicaceae family and is renowned for promoting memory and learning functions It has been shown to improve memory in Alzheimer's sufferers. It improves memory impairment brought on by ovariectomy, in part because of its antioxidant and acetylcholinesterase inhibitory effects. It increases the amount of acetylcholine.

1. **Tinospora cordifolia (Giloy):**

Tinospora cordifolia, a member of the Menispermaceae family, has the ability to improve memory in both animals with normal memory and those lacking it. Choline supplementation improves cognitive performance by immune-stimulating the body and enhancing acetylcholine production. Tinospora cordifolia is regarded as a memory and learning enhancer in Ayurveda. Tinospora cordifolia root aqueous extract improved verbal learning and logical memory.

**ANDROGRAPHOLIDE AND ITS ANALOGUES IN AD:**

**Varella Nallar et al 59:** Hippocampal neurogenesis declines in Alzheimer's disease (AD), and this has been linked to cognitive difficulties. We have previously demonstrated that the primary bioactive ingredient of Andrographis paniculate, andrographolide (ANDRO), stimulates proliferation in the hippocampus of the APPswe/PSEN1E9 (APP/PS1) mice model of AD. This proliferation was determined by labelling with the mitotic marker Ki67. Here, we expanded on how ANDRO affected hippocampus neurogenesis in APP/PS1 mice and assessed how much this process contributed to ANDRO's cognitive effects. Incorporating BrdU showed that 8-month-old APP/PS1 mice treated with ANDRO for 4 weeks had enhanced proliferation in the dentate gyrus. Neonatal immature neurons, neural progenitors, and neuroblasts were all cell types that were decreased in APP/PS1 animals compared to age-matched wild-type mice, despite ANDRO having no influence on neuronal differentiation of new-born cells. Immature neurons' migration, total dendritic length, arborization, and orientation were unaffected by ANDRO, indicating that it had no impact on the early morphological development of developing neurons. The performance of APP/PS1 mice in the object location memory task was also improved by ANDRO therapy. Co-treatment with the anti-mitotic medication TMZ did not completely reverse this impact, indicating that other. The observed improvement in cognition could be explained by the effects of ANDRO in addition to the rise in neurogenesis. Overall, our results show that ANDRO promotes proliferation in the hippocampus of APP/PS1 mice, which accelerates neurogenesis.

**Felipe G Serrano et al: Amyloid 60: (A)** oligomers play a major role in synaptic dysfunction and the loss of spatial memory that is linked to neuronal dysfunction in Alzheimer's disease (AD), a neurodegenerative condition. This impairment involves synaptic dysfunction brought on by the loss of synaptic proteins, which aids in the course of AD. It's interesting to note that the usage of natural substances is an emerging conceptual approach in the hunt for medications with therapeutic potentials for treating neurodegenerative diseases. In the current study, we report that andrographolide (ANDRO), a labdane diterpene extracted from Andrographis paniculata, increases the slope of field excitatory postsynaptic potentials (fEPSP) in the CA1 region of hippocampal slices, inhibits long-term depression (LTD), and protects long-term potentiation (LTP) against the damage induced by A oligomers in vitro, most likely by inhibiting Additionally, in two separate age groups of mice (7- and 12-month-old mice) used in an A-PPswe/PS-1 Alzheimer's model, ANDRO inhibits modifications in neuropathology. In hippocampi and cortices of 7-month-old mice, ANDRO decreases A levels, altering the ontogeny of amyloid plaques, and decreases tau phosphorylation around the A oligomeric species in both age groups. Furthermore, we found that ANDRO restores spatial memory abilities in two separate age groups, protecting synaptic plasticity and synaptic proteins in the process. Our findings imply that ANDRO may be employed as a viable preventive treatment for AD development.

**Rivera DS et al 61:** Dementia of the most frequent type is Alzheimer's disease (AD). A number of alterations in the brain, including the development of extracellular amyloid-beta (Ab) peptide aggregates and the intracellular buildup of hyperphosphorylated tau protein, are associated with the beginning and progression of this condition. Also mentioned are dysregulated neuroplasticity, synapse loss, and a decrease in cellular energy metabolism. The downregulation of canonical Wnt signalling in AD has also been demonstrated. Surprisingly, we previously demonstrated that in transgenic (Tg) and wild-type (WT) mice, the in vivo suppression of Wnt signalling promotes the emergence of AD markers. Furthermore, we discovered that Wnt signalling increases energy metabolism, which is essential for Wnt's capacity to support the restoration of cognitive function in AD. Therefore, we predicted that several symptoms in a presymptomatic transgenic animal model of AD would be alleviated by activating canonical Wnt signalling. To investigate the latter, we employed the J20 Tg transgenic mice model to examine the impact of andrographolide (ANDRO), a canonical Wnt signalling activator, on the mild AD phenotypic expression (high amounts of amyloid aggregates). In J20 Tg mice, we discovered that presymptomatic ANDRO treatment reduced the decline in cellular energy metabolism indicators. Moreover, the cognitive performance of the treated animals improved. Electrophysiological parameters demonstrated substantial abnormalities in presynaptic function in J20 Tg animals at the synaptic level, which were all fully recovered by ANDRO treatment. Finally, electron microscope study of hippocampus synaptosomes showed that ANDRO therapy restored the length of synapses. Together, these findings lend credence to the hypothesis that canonical Wnt signalling stimulation during presymptomatic stages may be a novel pharmaceutical approach to postpone the beginning of AD.

**CONCLUSION:**

The pharmacological effects of andrographolide on Alzheimer's disease are outlined in this review. Andrographolide is a compound derived from the traditional herb Andrographis paniculata (A. paniculata), which has a long history of use in eastern Asia and ancient China for the treatment of a variety of diseases, including laryngitis, rheumatoid arthritis, cancer, diarrhoea, and upper respiratory tract infections. Anti-inflammation, antioxidative stress, anti-apoptosis, and/or pro-apoptosis are some of the andrographolide's disease prevention and/or treatment methods. Andrographolide can pass the blood–brain barrier and distribute to various brain regions, according to pharmacodynamic studies, and as a result, its pharmacological effects on the central nervous system (CNS) have started to be understood in recent years. For instance, andrographolide has been shown to decrease the size of brain infarcts in many models of cerebral ischemia. Andrographolide inhibits neuroinflammatory response and synaptic dysfunction in models of Alzheimer's disease (AD), which may be demonstrated by the reversal of microglia-mediated production of pro-inflammatory cytokines as well as AD-associated decreases in synaptic proteins like postsynaptic membrane dense substance-95. Additionally, andrographolide may slow the start and/or progression of Parkinson's disease, multiple sclerosis, and cognitive impairment brought on by diabetes or surgery. Andrographolide has also been demonstrated to inhibit changes in hippocampal neurogenesis, mood-associated behavior, and abnormalities in serum corticosterone levels caused by chronic stress. These findings imply that andrographolide may have the potential to treat psychiatric conditions like anxiety and depression. In the early treatment of dementia and other disorders involving memory loss and Alzheimer's, herbs may hold promise. They are less toxic than pharmaceutical agents, which is one of their main advantages. Botanicals can be used in conjunction with medications or other complementary therapies including SAMe, fish oil, and antioxidant vitamins. The sooner treatment is started, the better the prognosis, according to a review of the research. In order to delay or potentially prevent the emergence of symptoms, clients who have family members with a history of Alzheimer's disease or other conditions affecting poor memory may start taking these therapies before symptoms appear.

Millions of individuals worldwide are afflicted by AD, a neurodegenerative condition. Families and societies may experience tremendous economic hardships as a result. The symptoms of AD cannot be effectively treated by medicine at this time. Researchers are working to create new medications with superior therapeutic efficacies. Andrographolide has been demonstrated to offer therapeutic effects in certain recent investigations effects in a variety of AD models. For instance, long-term andrographolide therapy (4 mg/kg, 3 months) has been demonstrated to prevent the decline in spatial learning and memory function in the South American rodent species Octodon degus. Pathology is similar to Alzheimer's in elderly people [27]. The mechanisms underlying this effect of andrographolide include I improvement of the field excitatory postsynaptic potential (fEPSP) in the stratum radiatum of the CA1 in the hippocampus, (ii) reversal of the decline in protein levels of AD hallmarks, such as synaptophysin (SYP), vesicular glutamate transporter 1 (vGluT1), and the GluN2A subunit of the NM These findings are consistent with those made in vitro, where it was discovered that andrographolide (10 M) treatment increased the slope of fEPSP in the CA1 of the hippocampus in normal wild-type mice, which then led to long-term depression (LTD) inhibition and long-term potentiation (LTP) enhancement in A oligomers-incubated hippocampal slices via inhibition of glycogen synthase kinase-3β (GSK-3β) activity and reversal of GluA2, GluN2B, and PSD-95 decrease.

**REFERENCES:**

1. Y. Dai, S.R. Chen, L. Chai, J. Zhao, Y. Wang, Y. Wang, Overview of pharmacological activities of Andrographis paniculata and its major compound andrographolide, Crit. Rev. Food Sci. Nutr. 10 (2018) 1–13.
2. U. Rasool, P.S.A. Parveen, S.K. Sah, H. S, Efficacy of Andrographis paniculata

against extended-spectrum β-lactamase (ESBL) producing E. coli, BMC Complement. Altern. Med. 18 (2018) 244.

1. L.S. Chua, Review on liver inflammation and anti-inflammatory activity of

Andrographis paniculata for hepatoprotection, Phytother. Res. 28 (2014)

1589–1598.

1. T. Suriyo, N. Pholphana, N. Rangkadilok, A. Thiantanawat, P. Watcharasit,

J. Satayavivad, Andrographis paniculata extracts and major constituent diterpenoids

inhibit growth of intraheptic cholagiocarcinoma cells by inducing cell cycle

arrest and apoptosis, Planta Med. 80 (2014) 533–543.

1. R.C. Saxena, R. Singh, P. Kumar, S.C. Yadav, M.P. Negi, V.S. Saxena, A.J. Joshua,

V. Vijayabalaji, K.S. Goudar, K. Venkateshwarlu, A. Amit, A randomized double

blind placebo controlled clinical evaluation of extract of Andrographispaniculata

(KalmCold) in patients with uncomplicated upper respiratory tract infection,

Phytomedicine 17 (2010) 178–185.

1. R.A. Burgos, J.L. Hancke, J.C. Bertoglio, V. Aguirre, S. Arriagada, M. Calvo,

D.D. Cáceres, Efficacy of an Andrographis paniculata composition for the relief of

rheumatoid arthritis symptoms: a prospective randomized placebo-controlled

trial, Clin. Rheumatol. 28 (2009) 931–946.

1. K. Bensch, J. Tiralongo, K. Schmidt, A. Matthias, K.M. Bone, R. Lehmann,

E. Tiralongo, Investigations into the antiadhesive activity of herbal extracts

against Campylobacter jejuni, Phytother. Res. 25 (2011) (2011) 1125–1132.

1. W.S.D. Tan, W. Liao, S. Zhou, W.S.F. Wong, Is there a future for andrographolide

to be an anti-inflammatory drug? Deciphering its major mechanisms of action,

Biochem. Pharmacol. 139 (2017) 71–81.

1. M.T. Islam, Andrographolide, a new hope in the prevention and treatment of

metabolic syndrome, Front. Pharmacol. 8 (2017) 571.

1. L. Wang, F. Cao, L.L. Zhu, P. Liu, Y.R. Shang, W.H. Liu, X. Dong, H.D. Bao, P. Gong,
2. Z.Y. Wang, Andrographolide impairs alpha-naphthylisothiocyanate-induced cholestatic liver injury in vivo, J. Nat. Med. 73 (2019) 388–396.
3. Y. Zhao, M. Wang, Y. Li, W. Dong, Andrographolide attenuates viral myocarditis

through interactions with the IL-10/STAT3 and P13K/AKT/NF-κβ signaling

pathways, Exp. Ther. Med. 16 (2018) 2138–2143.

1. R. Al Batran, F. Al-Bayaty, M.M. Al-Obaidi, M.A. Abdulla, Acute toxicity and the

effect of andrographolide on Porphyromonas gingivalis-induced hyperlipidemia in

rats, Biomed Res. Int. 2013 (2013) 594012.

1. S. Eugine Leo Prakash, R. Manavalan, Acute toxicity studies of andrographolide.

Research journal of pharmaceutical, Biol. Chem. Sci. 2 (2011) 547.

1. J.T. Coon, E. Ernst, Andrographis paniculata in the treatment of upper respiratory

tract infections: a systematic review of safety and efficacy, Planta Med. 70 (2004)

293–298.

1. A. Panossian, A. Hovhannisyan, G. Mamikonyan, H. Abrahamian,E. Hambardzumyan, E. Gabrielian, G. Goukasova, G. Wikman, H. Wagner,Pharmacokinetic and oral bioavailability of andrographolide from Andrographis paniculata fixed combination Kan Jang in rats and human, Phytomedicine 7(2000) 351–364.
2. R. Bera, S.K. Ahmed, L. Sarkar, T. Sen, S. Karmakar, Pharmacokinetic analysis and

tissue distribution of andrographolide in rat by a validated LC-MS/MS method,

Pharm. Biol. 52 (2014) 321–329.

1. X.B. Suo, H. Zhang, Y.Q. Wang, HPLC determination of andrographolide in rat

whole blood: study on the pharmacokinetics of andrographolide incorporated in

liposomes and tablets, Biomed. Chromatogr. 21 (2007) 730–734.

1. M. Li, H. Li, F. Fang, X. Deng, S. Ma, Astragaloside IV attenuates cognitive impairments induced by transient cerebral ischemia andreperfusion in mice via anti-inflammatory mechanisms, Neurosci. Lett. 639 (2017) 114–119.
2. R. Yang, S. Liu, J. Zhou, S. Bu, J. Zhang, Andrographolide attenuates microgliamediated Aβ neurotoxicity partially partially through inhibiting NF-κB and JNKMAPK signaling pathway, Immunopharmacol. Immunotoxicol. 39 (2017)

276–284.

1. D.S. Rivera, C. Lindsay, J.F. Codocedo, I. Morel, C. Pinto, P. Cisternas,

F. Bozinovic, N.C. Inestrosa, Andrographolide recovers cognitive impairment in a

natural model of Alzheimer’s disease (Octodon degus), Neurobiol. Aging 46 (2016)

204–220.

1. F.G. Serrano, C. Tapia-Rojas, F.J. Carvajal, J. Hancke, W. Cerpa, N.C. Inestrosa,

Andrographolide reduces cognitive impairment in young and mature APPswe/PS-

1 mice, Mol. Neurodegener. 9 (2014) 61.

1. T. Wang, B. Liu, W. Zhang, B. Wilson, J.S. Hong, Andrographolide reduces inflammation- mediated dopaminergic neurodegeneration in mesencephalic neuronglia cultures by inhibiting microglial activation, J. Pharmacol. Exp. Ther. 308

(2004) 975–983.

1. Z. Zhang, D. Lai, L. Wang, P. Yu, L. Zhu, B. Guo, L. Xu, L. Zhou, Y. Sun, S.M. Lee, Y. Wang, Neuroprotective effects of the andrographolide analogue AL-1 in the

MPP+/MPTP-induced Parkinson's disease model in vitro and in mice, Pharmacol.

Biochem. Behav. 122 (2014) 191–202.

1. M.I. Iruretagoyena, J.A. Tobar, P.A. González, S.E. Sepúlveda, C.A. Figueroa,

R.A. Burgos, J.K. Hancke, A.M. Kalergis, Andrographolide interferes with T cell

activation and reduces experimental autoimmune encephalomyelitis in the mouse,

J. Pharmacol. Exp. Ther. 312 (2005) 366–372.

1. L.M. Lien, C.C. Su, W.H. Hsu, W.J. Lu, C.L. Chung, T.L. Yen, H.C. Chiu, J.R. Sheu, K.H. Lin, Mechanisms of andrographolide-induced platelet apoptosis in human

platelets: regulatory roles of the extrinsic apoptotic pathway, Phytother. Res. 27

(2013) 1671–1677.

1. Y.Y. Chen, M.J. Hsu, C.Y. Hsieh, L.W. Lee, Z.C. Chen, J.R. Sheu, Andrographolide inhibits nuclear factor-κB activation through JNK-Akt-p65 signaling cascade in tumor necrosis factor-α-stimulated vascular smooth muscle cells, Transfus. Apher. Sci. 2014 (2014) 1–10.
2. W.J. Lu, K.H. Lin, M.J. Hsu, D.S. Chou, G. Hsiao, J.R. Sheu, Suppression of NF-κB signaling by andrographolide with a novel mechanism in human platelets: regulatory roles of the p38MAPK-hydroxyl radical-ERK2 cascade, Biochem.

Pharmacol. 84 (2012) 914–924.

1. Y. Ding, C. Shi, L. Chen, P. Ma, K. Li, J. Jin, Q. Zhang, A. Li, Effects of andrographolide on postoperative cognitive dysfunction and the association with NF-

κB/MAPK pathway, Oncol. Lett. 14 (2017) 7367–7373.

1. L.J. Estcourt, P.M. Fortin, S. Hopewell, M. Trivella, C. Doree, M.R. Abboud,

Interventions for preventing silent cerebral infarcts in people with sickle cell

disease, Cochrane Database Syst. Rev. 5 (2017) CD012389.

1. S. Bhaskar, P. Stanwell, D. Cordato, J. Attia, C. Levi, Reperfusion therapy in acute ischemic stroke: dawn of a new era? BMC Neurol. 18 (2018) 8.
2. P. Surinkaew, P. Sawaddiruk, N. Apaijai, N. Chattipakorn, S.C. Chattipakorn, Role of microglia under cardiac and cerebral ischemia/reperfusion (I/R) injury, Metab.

Brain Dis. 33 (2018) 1019–1030.

1. G. Hsiao, M.Y. Shen, K.H. Lin, C.Y. Chou, N.H. Tzu, C.H. Lin, D.S. Chou, T.F. Chen,

J.R. Sheu, Inhibitory activity of kinetin on free radical formation of activated platelets

in vitro and on thrombus formation in vivo, Eur. J. Pharmacol. 465 (2003) 281-287.

1. K. Grundler, R. Rotter, S. Tilley, J. Pircher, T. Czermak, M. Yakac, E. Gaitzsch, S. Massberg, F. Krötz, H.Y. Sohn, U. Pohl, H. Mannell, B.F. Kraemer, The proteasome regulates collagen-induced platelet aggregation via nuclear-factor-kappa-B (NFκB) activation, Thromb. Res. 148 (2016) 15–22.
2. C. Huang, L. Tong, X. Lu, J. Wang, W. Yao, B. Jiang, W. Zhang, Methylene blue

attenuates iNOS induction through suppression of transcriptional factor binding amid

iNOS mRNA transcription, J. Cell. Biochem. 116 (2015) 1730–1740.

36 E. Pineda-Molina, S. Lamas, Nitric oxide as a regulator of gene expression: studies

with the transcription factor proteins c-Jun and p50, Biofactors 15 (2001) 113–115.

37 J.R. Matthews, C.H. Botting, M. Panico, H.R. Morris, R.T. Hay, Inhibition of

NFkappaB DNA binding by nitric oxide, Nucleic Acids Res. 24 (1996) 2236–2242.

38 D.V. Krysko, T. Vanden Berghe, K. D’Herde, P. Vandenabeele, Apoptosis and

necrosis: detection, discrimination and phagocytosis, Methods 44 (2008) 205–221.

39 N. Plesnila, Role of mitochondrial proteins for neuronal cell death after focal cerebral

ischemia, Acta Neurochir. Suppl. (Wien) 89 (2004) 15–19.

40 T. Engel, N. Plesnila, J.H. Prehn, D.C. Henshall, In vivo contributions of BH3-only

proteins to neuronal death following seizures, ischemia, and traumatic brain injury,

J.Cereb. Blood Flow Metab. 31 (2011) 1196–1210.

41 P. Thisoda, N. Rangkadilok, N. Pholphana, L. Worasuttayangkurn, S. Ruchirawat,

J. Satayavivad, Inhibitory effect of Andrographis paniculata extract and its active

diterpenoids on platelet aggregation, Eur. J. Pharmacol. 553 (2006) 39–45.

42 Y.D. Li, B.Q. Ye, S.X. Zheng, J.T. Wang, J.G. Wang, M. Chen, J.G. Liu, X.H. Pei,

L.J. Wang, Z.X. Lin, K. Gupta, N. Mackman, A. Slungaard, N.S. Key, J.G. Geng, NF-

κB transcription factor p50 critically regulates tissue factor in deep vein thrombosis,

J. Biol. Chem. 284 (2009) 4473–4483.

43 M. Li, H. Li, F. Fang, X. Deng, S. Ma, Astragaloside IV attenuates cognitive

impairments induced by transient cerebral ischemia andreperfusion in mice via anti-

inflammatory mechanisms, Neurosci. Lett. 639 (2017) 114–119.

44 M. Poittevin, P. Lozeron, R. Hilal, B.I. Levy, T. Merkulova-Rainon, N. Kubis,

Smooth muscle cell phenotypic switching in stroke, Transl. Stroke Res. 5 (2014)

377–384.

45 W. Yao, Q. Sun, L. Huang, G. Meng, H. Wang, X. Jing, W. Zhang,

Tetrahydroxystilbene glucoside inhibits TNF-α-induced migration of vascular

smooth musclecells via suppression of vimentin, Can. J. Physiol. Pharmacol. 294

(2016) 155–160.

46 C.C. Chang, Y.F. Duann, T.L. Yen, Y.Y. Chen, T. Jayakumar, E.T. Ong, J.R. Sheu,

Andrographolide, a novel NF-κB inhibitor, inhibits vascular smooth muscle cell

proliferation and cerebral endothelial cell inflammation, Acta Cardiol. Sin. 30

(2014) 308–315.

47 C Li, J. He, X. Zhong, H. Gan, Y. Xia, CX3CL1/CX3CR1 axis contributes to

angiotensin II-induced vascular smooth muscle cell proliferation and inflammatory

cytokine production, Inflammation 41 (2018) 824–834.

48 H. Jing, S. Wang, M. Wang, W. Fu, C. Zhang, D. Xu, Isobavachalcone attenuates

MPTP-induced Parkinson’s disease in mice by inhibition of microglial activation

through NF-κB pathway, PLoS One 12 (2017) e0169560.

49 Q. Wang, Q. He, Y. Chen, W. Shao, C. Yuan, Y. Wang, JNK-mediated microglial

DICER degradation potentiates inflammatory responses to induce dopaminergic

neuron loss, J. Neuroinflam. 15 (2018) 184.

50 I.U. Song, J.S. Kim, S.W. Chung, K.S. Lee, Is there an association between the level

of high-sensitivity C-reactive protein and idiopathic Parkinson’s disease? A comparison

of Parkinson’s disease patients, disease controls and healthy individuals,

Eur. Neurol. 62 (2009) 99–104.

51 S. Iannaccone, C. Cerami, M. Alessio, V. Garibotto, A. Panzacchi, S. Olivieri,

G. Gelsomino, R.M. Moresco, D. Perani, In vivo microglia activation in very early

dementia with Lewy bodies, comparison with Parkinson’s disease, Parkinsonism

Relat. Disord. 19 (2013) 47–52.

52 G. Xu, Y. Li, K. Yoshimoto, G. Chen, C. Wan, T. Iwata, N. Mizusawa, Z. Duan,

J. Liu, J. Jiang, 2,3,7,8-Tetrachlorodibenzo-p-dioxin-induced inflammatory activation

is mediated by intracellular free calcium in microglial cells, Toxicology 308

(2013) 158–167.

53 G. Xu, Y. Li, K. Yoshimoto, Q. Wu, G. Chen, T. Iwata, N. Mizusawa, C. Wan, X. Nie,

2,3,7,8-Tetrachlorodibenzo-p-dioxin stimulates proliferation of HAPI microglia by

affecting the Akt/GSK-3β/cyclin D1 signaling pathway, Toxicol. Lett. 224 (2014)

(2014) 362–370.

54 W.F. Chiou, C.F. Chen, J.J. Lin, Mechanisms of suppression of inducible nitric

oxide synthase (iNOS) expression in RAW 264.7 cells by andrographolide, Br. J.

Pharmacol. 129 (2000) 1553–1560.

55 S.Y. Yu, L.J. Zuo, F. Wang, Z.J. Chen, Y. Hu, Y.J. Wang, X.M. Wang, W. Zhang,

Potential biomarkers relating pathological proteins, neuroinflammatory factors

and free radicals in PD patients with cognitive impairment: a cross-sectional study,

BMC Neurol. 14 (2014) 113.

56 M. Greter, F.L. Heppner, M.P. Lemos, B.M. Odermatt, N. Goebels, T. Laufer,

R.J. Noelle, B. Becher, Dendritic cells permit immune invasion of the CNS in an

animal model of multiple sclerosis, Nat. Med. 11 (2005) 328–334.

57 C. Sie, T. Korn, Dendritic cells in central nervous system autoimmunity, Semin.

Immunopathol. 39 (2017) 99–111.

58 Y. Dou, N. van Montfoort, A. van den Bosch, R.A. de Man, G.G. Zom, W.J. Krebber,

C.J.M. Melief, S.I. Buschow, A.M. Woltman, HBV-derived synthetic long peptide

can boost CD4+ and CD8+T-cell responses in chronic HBV patient’s ex vivo, J.

Infect. Dis. 217 (2018) 827–839.

59 Varela-Nallar L, Arredondo SB, Tapia-Rojas C, Hancke J, Inestrosa NC.

Andrographolide Stimulates Neurogenesis in the Adult Hippocampus. Neural Plast.

2015; 2015:935403. doi: 10.1155/2015/935403. Epub 2015 Dec 22. PMID: 26798521;

PMCID: PMC4700200.

60 Serrano FG, Tapia-Rojas C, Carvajal FJ, Hancke J, Cerpa W, Inestrosa NC.

Andrographolide reduces cognitive impairment in young and mature AβPPswe/PS-1

mice. Mol Neurodegener. 2014 Dec 18; 9:61. doi: 10.1186/1750-1326-9-61. PMID:

25524173; PMCID: PMC4414355.

61 Rivera DS, Lindsay C, Codocedo JF, Morel I, Pinto C, Cisternas P, Bozinovic F, Inestrosa

NC. Andrographolide recovers cognitive impairment in a natural model of Alzheimer's

disease (Octodon degus). Neurobiol Aging. 2016 Oct; 46:204-20. doi:

10.1016/j.neurobiolaging.2016.06.021. Epub 2016 Jul 5. PMID: 27505720.